WallStSmart
RLAY

Relay Therapeutics Inc

NASDAQ: RLAY · HEALTHCARE · BIOTECHNOLOGY

$12.57
-3.53% today

Updated 2026-04-29

Market cap
$2.41B
P/E ratio
P/S ratio
156.64x
EPS (TTM)
$-1.61
Dividend yield
52W range
$3 – $17
Volume
3.0M

Relay Therapeutics Inc (RLAY) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$82.65M$3.03M$1.38M$25.55M$10.01M$15.36M
Revenue growth (YoY)-96.3%-54.4%+1749.8%-60.8%+53.4%
Cost of revenue$2.15M$2.85M$3.55M$3.92M$4.13M$5.27M$5.46M$3.56M
Gross profit$-2.15M$-2.85M$79.11M$3.03M$1.38M$25.55M$10.01M$11.80M
Gross margin95.7%100.0%100.0%100.0%100.0%76.8%
R&D$41.03M$70.31M$99.86M$172.65M$246.35M$330.02M$319.09M$261.38M
SG&A$8.86M$13.74M$38.59M$57.39M$65.98M$74.95M$76.59M$56.71M
Operating income$-49.89M$-84.05M$-55.80M$-364.70M$-299.27M$-373.00M$-372.47M$-302.74M
Operating margin-67.5%-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
EBITDA$-47.73M$-81.20M$-52.25M$-223.08M$-306.82M$-374.15M$-380.21M$-272.92M
EBITDA margin-63.2%-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
EBIT$-49.89M$-84.05M$-55.80M$-227.01M$-310.95M$-379.42M$-385.67M$-276.48M
Interest expense$0.00$0.00$0.00$826000.00$8.77M
Income tax$1.10M$-8.80M$-3.40M$132.94M$-36.25M$-37.47M$-337.71M
Effective tax rate-2.3%11.7%6.1%-57.6%11.1%9.9%50.0%0.0%
Net income$-48.78M$-66.50M$-52.41M$-363.87M$-290.51M$-341.97M$-337.71M$-276.48M
Net income growth (YoY)-36.3%+21.2%-594.3%+20.2%-17.7%+1.2%+18.1%
Profit margin-63.4%-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%